References
- TenjinTMiyamotoSNinomiyaYProfile of blonanserin for the treatment of schizophreniaNeuropsychiatr Dis Treat2013958759423766647
- MiyamotoSDuncanGEMarxCELiebermanJATreatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugsMol Psychiatry20051017910415289815
- KaySRFiszbeinAOplerLAThe positive and negative syndrome scale (PANSS) for schizophreniaSchizophr Bull19871322612763616518
- KishiTMatsudaYNakamuraHIwataNBlonanserin for schizophrenia: systematic review and meta-analysis of double-blind, randomized, controlled trialsJ Psychiatr Res201347214915423131856
- KishiTMatsudaYIwataNCardiometabolic risks of blonanserin and perospirone in the management of schizophrenia: a systematic review and meta-analysis of randomized controlled trialsPLoS One201492e8804924505373
- ParkJIChoDHHahnSWThe advantage of using 3-week data to predict response to aripiprazole at week 6 in first-episode psychosisInt Clin Psychopharmacol2014292778523970176
- ChatterjeeAChakosMKoreenAPrevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patientsAm J Psychiatry199515212172417298526237
- CorrellCUManuPOlshanskiyVNapolitanoBKaneJMMalhotraAKCardiometabolic risk of second-generation antipsychotic medications during first-time use in children and adolescentsJAMA2009302161765177319861668
- LiuCCChienYLHsiehMHHwangTJHwuHGLiuCMAripiprazole for drug-naive or antipsychotic-short-exposure subjects with ultra-high risk state and first-episode psychosis: an open-label studyJ Clin Psychopharmacol2013331182323277261
- GaebelWRiesbeckMWölwerWMaintenance treatment with risperidone or low-dose haloperidol in first-episode schizophrenia: 1-year results of a randomized controlled trial within the German Research Network on SchizophreniaJ Clin Psychiatry200768111763177418052570
- KahnRSFleischhackerWWBoterHEffectiveness of antipsychotic drugs in first-episode schizophrenia and schizophreniform disorder: an open randomised clinical trialLancet200837196181085109718374841
- CorrellCUMalhotraAKKaushikSMcMenimanMKaneJMEarly prediction of antipsychotic response in schizophreniaAm J Psychiatry2003160112063206514594760
- LeuchtSBuschRKisslingWKaneJMEarly prediction of antipsychotic nonresponse among patients with schizophreniaJ Clin Psychiatry200768335236017388703
- LeuchtSZhaoJEarly improvement as a predictor of treatment response and remission in patients with schizophrenia: a pooled, post-hoc analysis from the asenapine development programJ Psychopharmacol201428438739424429222
- LeuchtSShamsiSABuschRKisslingWKaneJMPredicting antipsychotic drug response – replication and extension to six weeks in an international olanzapine studySchizophr Res20081011–331231918308513
- MiuraSClinical evaluation of blonanserin for schizophrenia: a randomized controlled study comparing blonanserin with riperidoneJpn J Clin Psychopharmacol200811297314
- MurasakiMClinical evaluation of blonanserin for schizophrenia: a double-blind trial comparing blonanserin with haloperidolJpn J Clin Psychopharmacol20071020592079
- GarciaERobertMPerisFNakamuraHSatoNTerazawaYThe efficacy and safety of blonanserin compared with haloperidol in acute-phase schizophrenia: a randomized, double-blind, placebo-controlled, multicentre studyCNS Drugs200923761562519552488
- YangJBahkWMChoHSEfficacy and tolerability of blonanserin in the patients with schizophrenia: a randomized, double-blind, risperidone-compared trialClin Neuropharmacol201033416917520661022
- MallinckrodtCHKaiserCJWatkinJGMolenberghsGCarrollRJThe effect of correlation structure on treatment contrasts estimated from incomplete clinical trial data with likelihood-based repeated measures compared with last observation carried forward ANOVAClin Trials20041647748916279288